Teva- Pharmaceutical Industries Long Term Debt

Teva- Pharmaceutical Industries posts a long-term debt of $12B as of June 2026. That compares with $17B in the prior-year period — down 27.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Teva- Pharmaceutical Industries's long-term debt was $17B. The latest reading is $12B — a 27.5% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Teva- Pharmaceutical Industries's financial statement story. At $12B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TEVA's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Teva- Pharmaceutical Industries's other metric pages and overview cover the third.

Judging Teva- Pharmaceutical Industries against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $12B here, then scan peer and history charts to see if the gap is persistent.